RGM.20.005 – Rational Engineering of a MODEL for OSsification (reMODELos)

Route: Regenerative medicine: game changer moving to broad areas of application

Cluster question: 100 How can we use cells, stem cells, and biomaterials to engineer and regenerate tissues and organs?

Bone tissue gives rise to the bodily structures that provide shape, protect vital organs, and enable movement. Additionally, bone tissue is the storage for minerals and the production site for red and white blood cells. Congenital, traumatic, and metabolic disorders can affect the function of bone tissue and tremendously limit a person’s quality of life; given the aspects of population growth and ageing, bone disorders represent a major burden on society and its healthcare costs.
Tissue engineering and biofabrication techniques have emerged over the last decade and changed the scientific landscape from both a fundamental and translational perspective, with lab-on-a-chip approaches and organoid cultures that mimic physiological tissue behavior in health and disease. For multiple tissue types, these techniques have enabled in-depth fundamental analyses on cellular behavior and interactions with other cell types. Translationally, such biomimetic models allow for screening of drug responsiveness, providing even a personalized medicine approach by using the patient’s own cells as cellular entities within such models.
The reMODELos consortium will focus on stepwise engineering of in vitro bone models to enable fundamental analysis of cell-cell and cell-material interactions, and translational screening for drug-responsiveness in biomimetic models of bone formation or bone resorption. Ultimately, these models will be combined to fabricate a full biomimetic model of bone homeostasis. The value of these models is evident for answering fundamental scientific questions related to cellular behavior in healthy bone as well as in pathological bone conditions, including osteoporosis, osteopenia, osteosarcoma and many rare genetic mutations or growth disorders. Further, the translational value of these models relates to the possibility to screen for effective, drug-based treatments, which might even enable a personalized medicine approach. Finally, these models are of societal value by decreasing ethical concerns regarding animal experimentation and lowering the numbers of laboratory animals required for either fundamental or translational experiments by academia and industry.

Keywords

biofabrication, bone, organoid, screening, tissue model

Other organisations

Maastricht University - VU Amsterdam - UMC Utrecht - TU, Tue - University of Twente - PolyVation BV - Kuros Biosciences BV - LifeTec Group - Corbion BV - Hogeschool Zuyd - Hogeschool Arnhem en Nijmegen - Stichting Proefdiervrij - Osteoporose Vereniging

Submitter

Organisation Radboudumc (RUMC)
Name Dr. J. (Jeroen) van den Beucken
E-mail jeroen.vandenbeucken@radboudumc.nl
Website www.regenerative-biomaterials.nl